NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $15.60 -0.48 (-2.99%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$16.02 +0.42 (+2.69%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Delcath Systems Stock (NASDAQ:DCTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Delcath Systems alerts:Sign Up Key Stats Today's Range$15.56▼$16.1550-Day Range$11.55▼$17.3652-Week Range$8.12▼$17.42Volume262,282 shsAverage Volume358,360 shsMarket Capitalization$541.32 millionP/E Ratio1,561.56Dividend YieldN/APrice Target$23.17Consensus RatingModerate Buy Company Overview Delcath Systems, Inc. (NASDAQ:DCTH) is an oncology company focused on developing and commercializing liver-directed therapies for patients with primary and metastatic cancers of the liver. Its technology is designed to deliver high concentrations of chemotherapy to the liver while limiting systemic exposure. The company’s primary product is the HEPZATO KIT, a combination of melphalan hydrochloride and the Hepatic Delivery System. The treatment is used to perform percutaneous hepatic perfusion, a procedure in which the liver is temporarily isolated so chemotherapy can be administered directly to it and then filtered before the blood returns to the patient’s circulation. In the United States, HEPZATO is approved for certain adults with unresectable metastatic uveal melanoma involving the liver. Delcath also markets the CHEMOSAT Hepatic Delivery System in select markets outside the United States, including Europe and Australia, where it is used by qualified medical centers for liver-directed chemotherapy procedures. The company’s products are intended for specialized cancer treatment settings and are distributed through healthcare providers and treatment centers. Delcath has historically concentrated on advancing hepatic perfusion technology through clinical development, regulatory approvals, and commercialization partnerships. The company is headquartered in New York and serves patients through specialized oncology centers in the United States and international markets.AI Generated. May Contain Errors. Read More Delcath Systems Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreDCTH MarketRank™: Delcath Systems scored higher than 57% of companies evaluated by MarketBeat, and ranked 410th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingDelcath Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDelcath Systems has a consensus price target of $23.17, representing about 48.5% upside from its current price of $15.60.Amount of Analyst CoverageDelcath Systems has only been the subject of 4 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($0.17) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is 1,561.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is 1,561.56, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.42.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.26% of the float of Delcath Systems has been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 6.93.Change versus previous monthShort interest in Delcath Systems has recently increased by 3.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.89 News SentimentDelcath Systems has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Delcath Systems this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for DCTH on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders19.36% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCTH Stock News HeadlinesDelcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by AnalystsSeptember 23 at 3:59 AM | americanbankingnews.comDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 11, 2026 | businesswire.com"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors. | SmartAsset (Ad)Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A CostSeptember 11, 2026 | finance.yahoo.comDelcath Systems Updates Corporate Bylaws and Governance FrameworkAugust 14, 2026 | tipranks.comThese two stocks hit fresh 52-week highs today – DCTH clocks best day in nearly 15 monthsAugust 6, 2026 | msn.comDelcath Systems, Inc. (DCTH) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comDelcath Systems to Participate at the Canaccord Genuity 46th Annual Growth ConferenceJuly 28, 2026 | finance.yahoo.comSee More Headlines DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $10.10 at the beginning of the year. Since then, DCTH stock has increased by 54.5% and is now trading at $15.60. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) announced its earnings results on Thursday, August, 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.16. The firm had revenue of $29.13 million for the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a trailing twelve-month return on equity of 0.46%. Read the conference call transcript. When did Delcath Systems' stock split? Delcath Systems shares reverse split on the morning of Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How will Delcath Systems' stock buyback program work? Delcath Systems' Board of Directors approved a share repurchase program on Thursday, November 20th 2025, which authorizes the company to buy back $25,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 8.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued. Who are Delcath Systems' major shareholders? Delcath Systems' top institutional shareholders include Bank of New York Mellon Corp (0.31%), IFP Advisors Inc (0.01%), Integrated Wealth Concepts LLC (0.01%) and California State Teachers Retirement System. Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura and Sandra Pennell. View institutional ownership trends. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Delcath Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC). Company Calendar Last Earnings8/06/2026Today9/25/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 DCTH's financial health is in the Green zone, according to TradeSmith. DCTH has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:DCTH CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees156Year Founded1988Price Target and Rating Average Price Target for Delcath Systems$23.17 High Price Target$32.00 Low Price Target$18.00 Potential Upside/Downside+48.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio1,561.56 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.70 million Net Margins0.56% Pretax Margin1.35% Return on Equity0.46% Return on Assets0.42% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio8.95 Sales & Book Value Annual Sales$85.23 million Price / Sales6.35 Cash Flow$0.05 per share Price / Cash Flow307.61 Book Value$3.15 per share Price / Book4.95Miscellaneous Outstanding Shares34,700,000Free Float27,981,000Market Cap$541.32 million OptionableOptionable Beta0.57 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:DCTH) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
